Literature DB >> 35638095

Robotic resection of isolated ovarian cancer recurrence in the lesser sac.

Jessica D St Laurent1,2, Jason N Silberman1,3, Michael J Worley1,2.   

Abstract

In recurrent ovarian cancer patients the addition of surgical cytoreduction is associated with prolonged overall survival compared to chemotherapy treatment alone when complete cytoreduction is achieved (Harter et al., 2021, Shi et al., 2021, Coleman et al., 2019). In the appropriate surgical candidates, a minimally invasive approach may be used to achieve complete cytoreduction of isolated lesions with proper exposure and surgical planning. This video demonstrates safe robotic entry into the lesser sac and resection of recurrent high-grade serous ovarian carcinoma near the pancreatic neck. The patient is a 78-year-old BRCA negative female with a history of a stage IIIC high-grade serous carcinoma. She previously underwent cytoreductive surgery and adjuvant chemotherapy in 2018 and presented 24 months later with a normal CA 125 and CT findings of an isolated lesion near the porta hepatis. An MRI was obtained preoperatively to further characterize the location of the lesion demonstrating a 2.2 × 1.6 cm hypoechoic mass adjacent to the pancreatic neck. Given the patient's prolonged disease-free interval, fitness for surgery and single site of disease, she met strict inclusion criteria for recent studies demonstrating clinical benefit with secondary cytoreduction (Harter et al., 2021, Shi et al., 2021). She was taken for a robotic secondary cytoreduction. At subsequent follow up 7 months later, our patient was still disease free and continues surveillance. In this video, we demonstrate the careful dissection of this isolated lesion from the omental bursa. We review important pre-procedural and anatomic considerations for robotic surgery in the lesser sac.
© 2022 The Authors. Published by Elsevier Inc.

Entities:  

Keywords:  Laparoscopy; Porta hepatis; Recurrence; Recurrent ovarian cancer; Secondary cytoreduction

Year:  2022        PMID: 35638095      PMCID: PMC9142552          DOI: 10.1016/j.gore.2022.100991

Source DB:  PubMed          Journal:  Gynecol Oncol Rep        ISSN: 2352-5789


Image 1:. Image 2:.

CRediT authorship contribution statement

Jessica D. St Laurent: Writing – original draft. Jason N. Silberman: . Michael J. Worley Jr.: Conceptualization, Supervision.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
  3 in total

1.  Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial.

Authors:  Tingyan Shi; Jianqing Zhu; Yanling Feng; Dongsheng Tu; Yuqin Zhang; Ping Zhang; Huixun Jia; Xiao Huang; Yunlang Cai; Sheng Yin; Rong Jiang; Wenjuan Tian; Wen Gao; Jihong Liu; Huijuan Yang; Xi Cheng; Rongyu Zang
Journal:  Lancet Oncol       Date:  2021-03-08       Impact factor: 41.316

2.  Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.

Authors:  Robert L Coleman; Nick M Spirtos; Danielle Enserro; Thomas J Herzog; Paul Sabbatini; Deborah K Armstrong; Jae-Weon Kim; Sang-Yoon Park; Byoung-Gie Kim; Joo-Hyun Nam; Keiichi Fujiwara; Joan L Walker; Ann C Casey; Angeles Alvarez Secord; Steve Rubin; John K Chan; Paul DiSilvestro; Susan A Davidson; David E Cohn; Krishnansu S Tewari; Karen Basen-Engquist; Helen Q Huang; Mark F Brady; Robert S Mannel
Journal:  N Engl J Med       Date:  2019-11-14       Impact factor: 91.245

3.  Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer.

Authors:  Philipp Harter; Jalid Sehouli; Ignace Vergote; Gwenael Ferron; Alexander Reuss; Werner Meier; Stefano Greggi; Berit J Mosgaard; Frederic Selle; Frédéric Guyon; Christophe Pomel; Fabrice Lécuru; Rongyu Zang; Elisabeth Avall-Lundqvist; Jae-Weon Kim; Jordi Ponce; Francesco Raspagliesi; Gunnar Kristensen; Jean-Marc Classe; Peter Hillemanns; Pernille Jensen; Annette Hasenburg; Sadaf Ghaem-Maghami; Mansoor R Mirza; Bente Lund; Alexander Reinthaller; Ana Santaballa; Adeola Olaitan; Felix Hilpert; Andreas du Bois
Journal:  N Engl J Med       Date:  2021-12-02       Impact factor: 91.245

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.